Karin Beelen

A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast Cancer

Katrien Berns, Hugo M. Horlings, Bryan T. Hennessy et al. · Cancer Cell · 2007 · 1.6K citations · Full text

Medicine, Molecular Biology, Oncology +17

Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes

Marcelo Sobral‐Leite, Izhar Salomon, Mark Opdam et al. · Breast Cancer Research · 2019 · 131 citations · Full text

Medicine, Immunology, Oncology +15

Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC).

Gabe S. Sonke, Annemiek van Ommen‐Nijhof, Noor Wortelboer et al. · Journal of Clinical Oncology · 2023 · 91 citations

Pharmacy, Endocrinology, Oncology +10

Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer

Gabe S. Sonke, Annemiek van Ommen‐Nijhof, Noor Wortelboer et al. · Nature · 2024 · 68 citations · Full text

Medicine, Oncology, Pharmacology +16

PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients

Karin Beelen, Mark Opdam, Tesa Severson et al. · Breast Cancer Research · 2014 · 62 citations · Full text

Medicine, Oncology, Pharmacology +17